Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

ESPR Esperion Therapeutics Inc

2,73

-0,14 (-4,88%)

19 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Esperion Therapeutics Charts.

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Esperion Therapeutics Charts.

News Esperion Therapeutics Inc

Form 144 - Report of proposed sale of securities
Dienstag 18 Juni 2024 (14 Stunden vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Dienstag 18 Juni 2024 (14 Stunden vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 28 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 24 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 24 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 24 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Esperion to Participate in Upcoming June Investor Conferences
Donnerstag 23 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
Mittwoch 22 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Montag 20 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
Montag 20 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Freitag 17 Mai 2024 (1 Monat vor) • Edgar (US Regulatory)

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
Dienstag 14 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Weitere Esperion Therapeutics Inc News-Artikel

BNP Paribas Issuance

3x Ark Innovati

BofA Finance LLC Autocal...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen